Outlook Therapeutics (NASDAQ:OTLK – Get Free Report) is scheduled to be issuing its quarterly earnings data before the market opens on Thursday, May 16th. Analysts expect the company to announce earnings of ($0.88) per share for the quarter.
Outlook Therapeutics (NASDAQ:OTLK – Get Free Report) last released its quarterly earnings data on Wednesday, February 14th. The company reported ($0.80) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.00) by $0.20. On average, analysts expect Outlook Therapeutics to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Outlook Therapeutics Stock Down 3.4 %
Shares of OTLK opened at $7.73 on Friday. The stock has a fifty day simple moving average of $8.50 and a two-hundred day simple moving average of $8.58. The company has a market capitalization of $100.59 million, a PE ratio of -1.93 and a beta of 0.28. Outlook Therapeutics has a 52-week low of $4.00 and a 52-week high of $40.60.
Analysts Set New Price Targets
Get Our Latest Report on Outlook Therapeutics
About Outlook Therapeutics
Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.
Further Reading
- Five stocks we like better than Outlook Therapeutics
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Will the Biotech Sector Shift From Lagger to Leader?
- What is a Low P/E Ratio and What Does it Tell Investors?
- Robinhood Soars: Dissecting a Record-Breaking Q1 2024
- 3 Healthcare Dividend Stocks to Buy
- Plug Power is Building the Future of Hydrogen Despite Headwinds
Receive News & Ratings for Outlook Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Outlook Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.